In NSCLC mouse model, specifically it was shown that in vivo injection of MRX34 generates the lower expression of PD-L1, but MRX34 can also boost tumor infiltration of CD8+ T cells and reduce CD8+PD1+ T cells (172). The gene discussed is CD8A; the disease is neoplasm.